Differential inflammasome expression and IL-1β secretion in monocyte-derived dendritic cells differentiated with IL-4 or IFN-α

Alessandra Pontillo1*, Bruna T Santillo2, Alberto JS Duarte2 and Telma M Oshiro2

Abstract

Background: NLRP3-inflammasome activation was evaluated in monocyte-derived dendritic cells (DC) obtained through IL-4 (IL4-DC) or IFN-α (IFN-DC) protocols and pulsed with chemically inactivated HIV-1. Inflammasome genes expression and IL-1β secretion were compared in DC isolated from 15 healthy subjects (HC) and 10 HIV-1 infected individuals (HIV+).

Findings: Whether HIV was able to increased NLRP3-inflammasome genes expression and IL-1β secretion in IL4-DC from HC, the induction of inflammasome appeared significantly reduced in IFN-DC from HC, suggesting a different responsive state of IFN-DC compared to IL4-DC. No inflammasome activation was observed in IL4-DC as well as in IFN-DC derived from HIV + subjects, confirming previous findings on “unresponsive” state of DC derived from HIV+ possibly due to chronic inflammatory state of these individuals.

Conclusions: Our results showed that IFN-α differently modulates inflammasome expression during monocytes-DC in vitro differentiation. These findings could be of interest considering the on-going research about DC manipulation and therapeutic strategies for HIV + involving DC-based immune-vaccines.

Keywords: HIV-1, Type-1 IFN, Dendritic cells, Inflammasome, NALP3, IL-1β, Vaccine, Immunotherapy

Findings

Background and aim
In the past ten years an increasing number of dendritic cell (DC)-based therapeutic vaccination trials against HIV-1 has been developed augmenting the general interest in dendritic cell biology and in the interaction between this innate immune cell and HIV-1 [1].

There are at least two major subtypes of DC: myeloid and plasmacytoid DC. Myeloid DC (mDC) are professional antigen presenting cell capable to initiate cellular immune response. On the other hand plasmacytoid DC (pDC) exhibit an exuberant anti-viral response through the production of high levels of IFN-alpha [2].

In HIV infection it has been demonstrated a reduction in absolute number of mDC and pDC, especially in patients with active HIV-1 replication [3], suggesting a key role of DC in controlling viral load. Moreover the preserved functionality of pDC isolated from “elite controllers” may be one of the mechanisms involved in the control of HIV-1 viremia in these subjects [4].

Myeloid DC obtained culturing peripheral blood monocytes with IL-4 and granulocyte-macrophage colony-stimulating factor (GM-CSF) (IL4-DC) have been implied in immunotherapy of cancer and, most recently, of HIV infection [5].

Alternative protocols for maturation of DC included the use of interferon (IFN)-α instead of IL-4 (IFN-DC). Type I interferons markedly promotes the differentiation of peripheral blood monocytes into DC. IFN-DC are able to induce a strong cytotoxic response and cross priming of CD8+ T cells against viral or tumoral antigens both in vitro and in vivo [6,7]. IFN-DC exhibit a combined phenotype of mDC and pDC associated with characteristics of natural killer (NK) cells [8,9].

In the context of therapeutic vaccine against HIV-1, the possibility of using IFN-DC would provide several advantages, including augmented antigen presentation, cytotoxic function and type I IFN production.

Considering the key role of NLRP3-inflammasome during maturation and activation of DC in mice [10],

* Correspondence: pontillo.a@gmail.com
1Laboratory of Immunogenetics, Departament of Immunology, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, Brazil
Full list of author information is available at the end of the article
our group has recently started working on inflammasome activation in DC obtained in vitro from peripheral blood monocytes. DC response to HIV-1 through NLRP3-inflammasome could be important in HIV vaccine development especially in DC-based immune treatment.

We demonstrated that human monocyte-derived IL4-DC presented an inducible activation of NLRP3-inflammasome by lipopolysaccharide/LPS as well as by HIV-1 [10]. It is interesting to note that the same differentiation protocol used in monocytes isolated from HIV+ individuals (HIV-DC) showed a different response. NLRP3-inflammasome was not induced by LPS or HIV in HIV-DC, however its basal activation resulted higher in these cells compared with DC from healthy subjects (HC-DC), letting us hypothesize an “unresponsive” condition of HIV-DC that may affect vaccine preparation [10].

In this study we investigate the rate of inflammasome expression and activation in monocyte-derived IFN-DC obtained from healthy individuals and HIV+ patients. Our findings could be of interest considering the on-going research about DC manipulation and therapeutic strategies for AIDS involving DC-based immune-vaccines.

**Individuals and methods**

15 healthy subjects (HC, 7 males, 8 females; mean age 30 ± 5 standard deviation/SD) and 10 HIV-1-positive volunteers (HIV+, 8 males, 2 females; mean age 28 ± 2 SD) were recruited from “Hospital das Clinicas” (University of São Paulo, Brazil). HIV+ patients had a CD4+ lymphocytes count > 500 cells/μl and were “naive” for treatment. All the patients have been infected for more than 5 years and they do not presented specific clinical symptoms at the moment of recruitment. Written informed consent was obtained according to the protocol of “Hospital das Clinicas” Ethical Committee (CAP Pesq) (São Paulo, Brazil).

Monocytes were isolated by adherence from peripheral blood monocytes obtained by centrifugation over Ficoll-Paque gradient and cultured at 1.5-2 × 10⁶/ml in AIM-V medium (Gibco) containing 50 ng/ml GM-CSF (Peprotech) and 50 ng/ml IL-4 (Peprotech) or IFN-α (Schering-Plough) (IL4-DC and IFN-DC, respectively). On day 5, DC were pulsed with 0.5 × 10⁹ particles of alditritol-2 inactivated HIV (as reported in [10]) for 4 hours. Supernatants were harvested and used for IL-1β secretion dosage; cells were lysed for mRNA isolation and gene expression analysis.

![Figure 1](http://www.aidsrestherapy.com/content/10/1/35)
Total RNA was isolated using the RNAqueous micro kit (Ambion, Life Technologies) and retro-transcribed with the SuperScritp-II kit (Invitrogen). NLRP1, NLRP3, NLRC4, AIM2, CASP1, IL1B genes were amplified with specific TaqMan® Gene Expression Assays (Applied Biosystems) using the ABI 7300 platform (Applied Biosystems). ACTB was the housekeeping gene used for normalization. Fold-change (FC) genes expression was calculated comparing stimulated (+HIV) and untreated/resting cells as $2^{-\Delta \Delta CT}$ following the indications of Livak et al. [11].

The secreted IL-1β was evaluated with ELISA (BD Biosciences Pharmigen). Results were expressed as pg/ml.

One-way Anova analysis was used to compare different groups and a significance level of 0.05 was applied. Prism 5.01 software (GraphPad Software, Inc) was used for done graphs and statistical analysis.

**Results and discussion**

We evaluated the expression of NLRP1, NLRP3, NLRC4, AIM2, CASP1, IL1B genes in DC from 15 healthy subjects obtained through IL-4 or IFN-α differentiation protocol and pulsed with chemically inactivated HIV-1. IL-1β secretion was also evaluated as marker of inflammasome activation.

Cells differentiation state was checked by flow cytometry looking at granulosity and common DC markers (Additional file 1: Figure S1). No significant differences were observed in differentiation markers between IL4-DC and IFN-DC.

When genes expression was evaluated the following criteria were applied: only samples with Ct < 35 and with a positivity of at least 80% of the samples were included in the analysis; normalized data (ΔCT) must be homogenous for all the genes in each group (t test p-value > 0.05); FC > 1.5 or <0.5 were taken in account as up-regulation or down-regulation.

HIV induced increased expression (FC > 1.5) of NLRP1, NLRP3, AIM2, CASP1 and IL1B in IL4-DC, and of NLRC4, AIM2, CASP1 and IL1B in IFN-DC (Figure 1A). However the rate of induction appeared to be significantly reduced in IFN-DC compared to IL-4 DC (p < 0.003).

Of note HIV-1 was able to increase NLRP3 expression in IL4-DC (FC = 22.47), but it was not able to do the same in IFN-DC (FC = 1.24) (p < 0.003) (Figure 1A).

These differences in inflammasome genes expression between IL4-DC and IFN-DC were emphasized by the results obtained from IL-1β secretion analysis in DC supernatants. HIV induced a significant increase of the pro-inflammatory cytokine in IL4-DC (+HIV = 186.5 pg/ml versus Untreated = 74.87 pg/ml; p = 0.026) but not in IFN-DC (+HIV = 21.88 pg/ml versus Untreated = 8.65 pg/ml).

![Figure 2](http://www.aidsrestherapy.com/content/10/1/35)
ml; p = 0.301) (Figure 1B). Basal secretion of IL4-DC appeared augmented compared to IFN-DC however not in a statistically significant way.

These findings suggested that chemically inactivated HIV-1 is able to induce NLRP3-inflammasome activation in IL4-DC but not in IFN-DC.

As we previously hypothesized [10] NLRP3-inflammasome could play a role in response against HIV and could participate to full dendritic cell activation and to increased proliferation of specific HIV-induced T cells. However our new findings point out that the protocol implied to differentiate monocytes to DC could affect inflammasome biology. Our results agreed with previously reported data by Guarda et al. [12] about the ability of type I IFNs to suppress pro-IL-1 levels and decrease the activity of NLRP1 and NLRP3-inflammasomes in mice. Moreover it is well known that the activation of NLRP3-inflammasome in DC is related with the ability to induce a Th17 polarization in naïve T cells [13], while IFN-DC are able to induce Th1 but fail to polarize naïve T cells into Th17 [14], letting us hypothesize that in IFN-DC the inflammasomes are not induced.

When DC derived from HIV + individuals were analysed, we observed that HIV was not able to significantly induce any of the inflammasome genes in IL4-DC as well as in IFN-DC (1.5 < FC < 0.5) (Figure 2A). According to our previous published data [10], in untreated cells IL1-β secretion was higher in HIV-DC compared to HC-DC whatever protocol was used (Figure 1B and 2B; p = 0.02). Moreover HIV was not able to induce augmented amount of cytokine in IFN-DC or in IL4-DC (Figure 2B). We have previously hypothesized that IL4-DC from HIV + individuals presented an increased basal activation of NLRP3-inflammasome possibly due to the well-known chronic inflammatory state of HIV + patients leading to an “unresponsive” state of monocyte-derived DC [10]. Our findings emphasized once more that this condition is independent of the protocol used for monocyte-DC differentiation.

We are aware that this study is preliminary and that deep investigation about the functionality of IFN-DC is needed, such as ability to activate a lymphocytes specific response, but we would emphasize the importance of DC differentiation protocol in experimental design. Moreover, considering the on-going trials of DC-based immune treatment against HIV-1 [15] it is interesting to remember that the in vitro manipulation of DC could be a limited step in vaccine preparation. Whether it will be fully demonstrated the role of NLRP3-inflammasome in human DC maturation/activation and the impact of inflammasome induction in lymphocyte specific response, our findings suggest that protocols using IL-4 may represent a better choice than IFN ones.

Additional file

Additional file 1: Figure S1. Characterization of monocyte-derived dendritic cells. Generated immature monocyte-derived dendritic cells obtained by IFN (IFN-DC) (A) or IL-4 (IL4-DC) (B) protocols for common markers expression (CD11c, HLA-DR, CD80, CD86, CD83, CD1a, CCRT). Cells were CD14 negative. Average percentage of positive cells and standard error were reported for healthy individuals (n = 15) stimulated or not with HIV (+HIV and Untreated, respectively).

Abbreviations
DC: Monocyte-derived dendritic cells (DCs); IL: Interleukin; IL-4:IL-4-DC: Monocyte-derived dendritic cells obtained by IL-4 and GM-CSF protocol; IFN-DC: Monocyte-derived dendritic cells obtained by IFN-α and GM-CSF protocol; HC: Healthy subjects; HIV+: HIV-1 infected individuals.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
A.P. conceived of the study, coordinated its design, performed statistical analysis and wrote the manuscript; B.T.S. carried out the experiments; A.J.S.D. is the responsible of the laboratory and revised the work critically; T.M.H. is the responsible of the work group, contributed in conceiving and designing the study, analysis and interpretation of data and drafting the manuscript. All authors read and approved the final manuscript.

Authors’ information
A.P., PhD, works on inflammasome genetics and biology; B.T.S. is a pre-PhD student working on DC biology; A.J.S.D., Prof, is the principal investigator of the on-going clinical trial of DC-based immune treatment against HIV-1; T.M.H, PhD, works on DC biology and she’s the supervisor of the group involved in the preparation of DC for anti-HIV immune therapy.

Acknowledgements
This work was supported by the Sao Paulo Research foundation (FAPESP). We thank Alexandre de Almeida for HIV + patients recruitment.

Author details
1Laboratory of Immunogenetics, Department of Immunology, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, Brazil. 2Laboratory of Medical Investigation in Dermatology and Immunodeficiency, LIM-56, Faculty of Medicine, University of Sao Paulo, Sao Paulo, Brazil.

Received: 20 June 2013 Accepted: 3 December 2013 Published: 27 December 2013

References
1. McMichael AJ, Borrow P, Tomaras GD, Gocnoffileke N, Haynes BF: The immune response during acute HIV-1 infection: clues for vaccine development. Nature Reviews Immunol 2010, 10:11–23.
2. Siegel FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shah K, Ho S, Antonenko S, Liu YJ: The nature of the principal type 1 interferon-producing cells in human blood. Science 1999, 284(5421):1835–1837.
3. Barron MA, Blyeveis N, Palmer BE, MaWhinney S, Wilson CC: Influence of plasma viremia on defects in number and immunophenotype of blood dendritic cell subsets in human immunodeficiency virus 1-infected individuals. J Infect Dis 2003, 187(1):26–37.
4. Machmach K, Leal M, Gras C, Viciana P, Genebat M, Franco E, Boufassa F, Lambotte Q, Herbeuval JP, Ruiz-Mateos E: Plasmacytoid dendritic cells reduce HIV production in elite controllers. J Virol 2012, 86(8):4245–4252.
5. Rinaldo CR: Dendritic cell-based human immunodeficiency virus vaccine. J Intern Med 2009, 265(1):138–158.
6. Lapenta C, Santini SM, Spada M, Donati S, Urbani F, Accapezzato D, Franceschini D, Andreotti M, Barnaba V, Belardelli F: IFN-alpha-conditioned dendritic cells are highly efficient in inducing cross-priming CD8(+) T cells against exogenous viral antigens. Eur J Immunol 2006, 36(8):2046–2060.
7. Parlati S, Romagnoli G, Spadaro F, Canini I, Stabella P, Borghi P, Ramoni C, Fileisi I, Biocca S, Gabriele L, Belardelli F: LOX-1 as a natural IFN-alpha-
mediated signal for apoptotic cell uptake and antigen presentation in dendritic cells. Blood 2010, 115(8):1554–1563.

8. Korthals M, Safaian N, Kronenwett R, Mahöfer D, Schott M, Papewalis C, Diaz Blanco E, Winter M, Czibere A, Haas R, Kobbe G, Fenk R: Monocyte derived dendritic cells generated by IFN-alpha acquire mature dendritic and natural killer cell properties as shown by gene expression analysis. J Transl Med 2007, 5:46.

9. Farkas A, Kemény L: Interferon-α in the generation of monocyte-derived dendritic cells: recent advances and implications for dermatology. Br J Dermatol 2011, 165(2):247–254.

10. Schroder K, Tschopp J: The inflammasomes [review]. Cell 2010, 140(2):821–832.

11. Pontillo A, Silva LT, Oshiro TM, Crevella S, Duarte AJ: HIV-1 induces NALP3-inflammasome expression and interleukin-1β secretion in dendritic cells from healthy individuals but not from HIV-positive patients. AIDS 2012, 26(1):11–18.

12. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods 2001, 25(4):402–408.

13. Guarda G, Braun M, Staehli F, Tardivel A, Mattmann C, Förster I, Farlik M, Decker T, Du Pasquier RA, Romero P, Tschopp J: Type I interferon inhibits interleukin-1 production and inflammasome activation. Immunity 2011, 34(2):213–223.

14. Mills KH, Dungan LS, Jones SA, Harris J: The role of inflammasome-derived IL-1 in driving IL-17 responses. J Leukoc Biol 2013, 93(4):489–497.

15. García F, Routy JP: Challenges in dendritic cells-based therapeutic vaccination in HIV-1 infection Workshop in dendritic cell-based vaccine clinical trials in HIV-1. Vaccine 2011, 29(38):6454–6463.

doi:10.1186/1742-6405-10-35
Cite this article as: Pontillo et al.: Differential inflammasome expression and IL-1β secretion in monocyte-derived dendritic cells differentiated with IL-4 or IFN-α. AIDS Research and Therapy 2013 10:35.